title: Prognostic value of metabolic tumour volume and total lesion glycolysis in18F-FDG PET/CT scans in locally advanced breast cancer staging.
abstract: OBJECTIVE
  To determine whether metabolic tumour volume (MTV) and total lesion glycolysis (TLG) are able to predict recurrence risk in locally advanced breast cancer (LABC) patients.
  
  
  METHODS
  Retrospective study of LABC patients who undertook neoadjuvant, local and adjuvant treatment and follow up. A18F-FDG PET/CT study for initial staging was performed analysing in this study different metabolic parameters (MTV, TLG, SUVmax and SUVmed) both in the primary tumour (T) as well as in axillary nodes (N) and whole-body (WB).
  
  
  RESULTS
  Forty females were included between January 2010-2011; follow up until January 2015 was completed. The average follow-up was 46 months. Twenty percent presented recurrence: local disease (n=2) and distant metastasis (n=6); 3 patients died (38% of the patients which recurred and 7.5% from the total). SUVmax, MTV and TLG, in T, N and WB, were higher in those patients with recurrence. The MTV and TLG parameters in the tumour (T) were related to the recurrence rate (P=.020 and P=.028, respectively); whereas SUVmax in the lymph nodes (N) was significantly related (P=.008) to the recurrence rate. The best cut-off points to predict recurrence where: MTV T ≥19.3cm3, TLG T≥74.4g and SUVmax N≥13.8, being 10-12 times more likely to recidivate when these thresholds where exceeded. Tumour grade was the only clinical-pathological variable which was related to recurrence probability (p=.035).
  
  
  CONCLUSIONS
  In this study of LABC patients the metabolic parameters which have a better relationship with recurrence rate are: MTV and TLG in the primary tumour, SUVmax in the regional lymph node disease and whole-body PET data.
authors.affiliation: Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España. Electronic address: anajimenezb@hotmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Jiménez-Ballvé
authors.affiliation: Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
authors.forename: M
authors.initials: M
authors.lastname: García García-Esquinas
authors.affiliation: Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
authors.forename: O
authors.initials: O
authors.lastname: Salsidua-Arroyo
authors.affiliation: Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
authors.forename: A
authors.initials: A
authors.lastname: Serrano-Palacio
authors.affiliation: Servicio de Oncología Médica, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
authors.forename: J A
authors.initials: JA
authors.lastname: García-Sáenz
authors.affiliation: Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
authors.forename: A
authors.initials: A
authors.lastname: Ortega Candil
authors.affiliation: Unidad de Gestión Clínica de Medicina Preventiva, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
authors.forename: M E
authors.initials: ME
authors.lastname: Fuentes Ferrer
authors.affiliation: Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
authors.forename: C
authors.initials: C
authors.lastname: Rodríguez Rey
authors.affiliation: Servicio de Ginecología y Obstetricia, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
authors.forename: J M
authors.initials: JM
authors.lastname: Román-Santamaría
authors.affiliation: Servicio de Oncología Médica, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
authors.forename: F
authors.initials: F
authors.lastname: Moreno
authors.affiliation: Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
authors.forename: J L
authors.initials: JL
authors.lastname: Carreras-Delgado
mesh_terms: D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006019:Glycolysis; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D000072078:Positron Emission Tomography Computed Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D047368:Tumor Burden
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: (18)F-FDG; Carcinoma localmente avanzado de mama; Glucólisis tumoral total; Locally advanced breast cancer; Metabolic tumour volume; PET/CT; PET/TC; Total lesion glycolysis; Volumen metabólico tumoral